SGLT2 Inhibitors Reduce Alzheimer’s Risk by 43%: New Study Findings
Recent clinical research indicates that patients prescribed SGLT2 inhibitors—a class of medication primarily used to treat type 2 diabetes—may experience a significantly lower risk of developing Alzheimer’s disease. Data suggest that the anti-inflammatory and metabolic benefits of these drugs could play a protective role in neurological health, potentially reducing the incidence of dementia by 43% … Read more